Clinical Trials
35 trialsCAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics Inc
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Vasgene Therapeutics, Inc
KICKSTART
Effector Therapeutics
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
R-Pharm
MK-3475-E90
Wellmarker Bio
Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms
R-Pharm
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Provectus Pharmaceuticals
FIH
BJ Bioscience, Inc.
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
Biocad
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies
Biocad
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
Ribon Therapeutics, Inc.
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
OncoSec Medical Incorporated
Keynote-695
OncoSec Medical Incorporated
A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver
Taizhou Hanzhong biomedical co. LTD
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Curegenix Inc.
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Accendatech USA Inc.
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Monopteros Therapeutics Inc.
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NSABP FB-14
NuGenerex Immuno-Oncology
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody
Harbour BioMed (Guangzhou) Co. Ltd.
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen
NanoCarrier Co., Ltd.
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Taizhou Hanzhong biomedical co. LTD
FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
NO3DEXPL
Nilogen Oncosystems
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
Lycera Corp.
Pembro
Mediclinic Middle East
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Virogen Biotechnology Inc.